Lipocine Inc.
Lipocine Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 1, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
Cash runway is approximately 30.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 8 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 1, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| August 15, 2027 | Brexanolone Lifting Outcomes Of Moms | Trial Milestone | Phase 3 |
Track LPCN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open LPCN in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| October 7, 2026 | 8-K filed: Other event | Filing | — |
| September 16, 2026 | 8-K filed: Other event | Filing | — |
| September 14, 2026 | 8-K filed: Other event | Filing | — |
| September 11, 2026 | 8-K filed: Other event | Filing | — |
| September 10, 2026 | 8-K filed: Other event | Filing | — |
| August 21, 2026 | 8-K/A filed: Leadership change | Corporate | — |
| August 4, 2026 | Quarterly results filed (8-K) | Earnings | — |
| August 3, 2026 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| June 12, 2026 | 8-K filed: Other event | Filing | — |
| June 4, 2026 | 8-K filed: Other event | Filing | — |
| June 4, 2026 | 8-K filed: Leadership change | Corporate | — |
| May 26, 2026 | 8-K filed: Other event | Filing | — |
| May 19, 2026 | 8-K filed: Other event | Filing | — |
| May 18, 2026 | 8-K filed: Other event | Filing | — |
| May 7, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 7, 2026 | 8-K filed: Other event | Filing | — |
| April 21, 2026 | 8-K filed: Leadership change | Corporate | — |
| April 2, 2026 | 8-K filed: Other event | Filing | — |
| April 2, 2026 | 8-K filed: Other event | Filing | — |
| March 10, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 4, 2026 | 8-K filed: Other event | Filing | — |
| February 18, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 18, 2026 | 8-K filed: Other event | Filing | — |
| January 20, 2026 | 8-K filed: Other event | Filing | — |
| January 16, 2026 | A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | Trial Milestone | Phase 3 |
| January 12, 2026 | 8-K filed: Other event | Filing | — |
| January 12, 2026 | 8-K filed: Other event | Filing | — |
| December 16, 2025 | 8-K filed: Other event | Filing | — |
| December 15, 2025 | 8-K filed: Leadership change | Corporate | — |
| December 11, 2025 | 8-K filed: Other event | Filing | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.